Contrasting Centogene (NASDAQ:CNTG) & Fortrea (NASDAQ:FTRE)

Centogene (NASDAQ:CNTG) and Fortrea (NASDAQ:FTRE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Valuation and Earnings

This table compares Centogene and Fortrea”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centogene	$48.54 million	0.00	-$38.58 million	N/A	N/A
Fortrea	$3.01 billion	0.52	-$3.40 million	($1.39)	-12.68

Fortrea has higher revenue and earnings than Centogene.

Risk and Volatility

Centogene has a beta of -0.67, indicating that its stock price is 167% less volatile than the S&P 500. Comparatively, Fortrea has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Centogene and Fortrea, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centogene	0	0	0	0	N/A
Fortrea	1	8	2	1	2.25

Fortrea has a consensus target price of $23.60, indicating a potential upside of 33.26%.

Insider & Institutional Ownership

9.9% of Centogene shares are owned by institutional investors. 1.9% of Centogene shares are owned by insiders. Comparatively, 0.1% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Centogene and Fortrea’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Centogene	N/A	N/A	N/A
Fortrea	-10.09%	1.98%	0.78%

Summary

Fortrea beats Centogene on 7 of the 10 factors compared between the two stocks.

About Centogene

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.